Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Lung Therapeutics Inc
Profile last edited on: 8/28/19      CAGE: 6VDT5      UEI: KG3AMMKMEWE9

Business Identifier: Therapies for orphan pulmonary diseases: idiopathic pulmonary fibrosis and pleural effusion
Year Founded
2013
First Award
2018
Latest Award
2020
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2801 Via Fortuna Suite 425
Austin, TX 78746
   (512) 872-7527
   N/A
   www.lungtx.com
Location: Single
Congr. District: 21
County: Travis

Public Profile

Lung Therapeutics, Inc. is a clinical stage biopharmaceutical company structured around leveraging decades of leading research in orphan, pulmonary indications for which there are unmet medical needs. The company is developing a proprietary pipeline of novel therapeutics with the potential to greatly improve outcomes over currently available treatments. Lung Therapeutics lead drug, LTI-01, is in development for Loculated Pleural Effusion (LPE) and has successfully completed a clinical trial in LPE patients. The company’s second drug candidate, LTI-03, is in development for Idiopathic Pulmonary Fibrosis and is ready to enter clinical development

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$750,225
Phase II Dollars
$0
Total Awarded
$750,225

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2020 1 NIH $300,228
Project Title: Development and Testing of Subcutaneous CSD Peptide Formulations for Chronic Kidney Disease
2019 1 NIH $225,000
Project Title: Caveolin-1 Replacement Therapy for the Treatment of Idiopathic Pulmonary Fibrosis
2018 1 NIH $224,997
Project Title: Enhancement of the Beneficial Effects of Mesenchymal Stem Cell (MSC) Treatment by the Caveolin-1 Scaffolding Domain Peptide (CSD)
0 1 NIH $259,332
Project Title: The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)

Key People / Management

  Brian Windsor -- CEO

  Charles Garner -- CFO

  Steven Idell -- Founder & Chief Scientific Officer

  Matt Karpen -- Director of CMC

  Breanne Mackenzie

  Andrew Mazar -- Founder and Head of Product Development

  Elena Tourkina

Company News

There are no news available.